During the past decade, Fox Chase Cancer Center; Hematology/Oncology conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 1 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Fox Chase Cancer Center; Hematology/Oncology" are "Diffuse Large B-Cell Lymphoma" (1 trials), "Non-Small Cell Lung Cancer" (1 trials) and "Renal Cell Carcinoma" (1 trials). Many other conditions were trialed in "Fox Chase Cancer Center; Hematology/Oncology" in a lesser frequency.

Most popular intervention types in "Fox Chase Cancer Center; Hematology/Oncology" are "Drug" (3 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (2 trials), "Cyclophosphamide" (1 trials), "Doxorubicin" (1 trials), "Placebo" (1 trials) and "Polatuzumab Vedotin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Fox Chase Cancer Center; Hematology/Oncology" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Fox Chase Cancer Center; Hematology/Oncology". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Fox Chase Cancer Center; Hematology/Oncology, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Fox Chase Cancer Center; Hematology/Oncology, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".